Lipid mediators and their signaling in ocular surface inflammation and meibomian gland dysfunction
Lipid mediators and their signaling in ocular surface inflammation and meibomian gland dysfunction
批准号:
10514592
负责人:
Anat Galor
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-10-01 至 2024-09-30
关键词:
AffectAgeAnti-Inflammatory AgentsArachidonic AcidsBiologicalBiological AssayCell DeathCell LineCell SurvivalCeramidesClinicalClinical DataComplexCytoplasmDinoprostoneDiseaseDocosahexaenoic AcidsEicosanoidsEicosapentaenoic AcidEpithelial CellsEvaluationEyeFemaleFilmFoundationsFrequenciesFunctional disorderGoalsHumanIn VitroIndividualInflammationInflammation MediatorsInflammatoryKnowledgeLaboratoriesLinkLipidsMeasuresMediatingModelingMolecularMorbidity - disease rateNatureOmega-3 Fatty AcidsOmega-6 Fatty AcidsPainPathway interactionsPatientsPhospholipase A2Pilot ProjectsPolyunsaturated Fatty AcidsProductionProstaglandinsProteinsPublishingQuality of lifeRegression AnalysisResearchRoleSample SizeSamplingSignal TransductionSigns and SymptomsSphingolipidsSphingomyelinaseSphingomyelinsStressSymptomsTestingTimeVeteransVisualWorkaqueousbaseceramide 1-phosphatedisorder subtypeevaporationeye drynessimprovedin vitro Modelin vivo Modelinflammatory markerlipid mediatormalemeibomian glandmeibomian gland dysfunctionmilitary veteranmodel buildingmolecular targeted therapiesmultiplex assaynovelocular surfaceprospectivesphingosine 1-phosphatetherapeutic developmenttherapeutic targettreatment optimization
中文摘要
干眼症(DE)影响五分之一的退伍军人,并影响生活质量。这是一种复杂的疾病,
多种症状(如疼痛、视觉障碍)和体征(如泪液分泌减少、泪液分泌增加)
蒸发)。DE的关键病理生理成分是眼表炎症和睑板腺
功能障碍(MGD)。尽管它的频率和发病率,目前的治疗并不能缓解症状,
患者为了适当地管理DE,有必要了解机制和具体的
疾病亚型的贡献者。本提案的总体目标是通过研究提高这方面的知识,
生物活性鞘脂(SPL)在MGD和DE的其他方面的作用。我们的初步和公布的
研究表明,SPL成分变化(鞘磷脂(SM)/神经酰胺(Cer)比值升高)质量较差
睑板腺分泌物(睑脂);促炎(ω-6)/促消退(ω-3)脂质的比例较高,以及
DE患者泪液中前列腺素E2水平较高。通过SM产生的生物活性Cer
鞘磷脂酶(SMase)及其衍生物,神经酰胺1-磷酸和鞘氨醇1-磷酸,
炎性脂质,并可诱导形成其他炎性脂质,如洋地黄素。我们检测到
人眼泪中的SMase活性。在这个建议中,我们将测试的假设,在SPL组成的变化,
睑脂导致DE的各种体征,包括眼表炎症、泪膜紊乱和角膜炎。
MGD。在目标1中,我们将分析睑脂和泪液SPL以及促炎和抗炎PUFA和类二十烷酸
通过LC-MS/MS从120个病例(睑脂质量差)和120个对照(睑脂质量正常)中选择,
我们前瞻性地从一个庞大的退伍军人群体中收集样本,
(mean年龄62 ± 10岁; 467名男性,46名女性; 230名白色,272名黑人)。相关和回归分析将
以临床数据为因变量,以脂质介质为自变量。在目标2中,
将从对应于样品的240个Schirmer条带中测定SMAse(酸性和中性)的活性
目标1。然后,我们将建立模型,研究SMase活性、SPL和眼表之间的关系
炎症在目标3中,我们将在体外实验中确定SPL和炎症之间的分子联系。
通过使用人永生化睑板腺上皮细胞系(HMGEC)的模型来测试
生物活性SPL在正常和高渗条件下介导炎症、细胞活力、细胞死亡等。
影响:我们的结果将通过MGD状态识别SPL差异,阐明生物活性之间的关系,
SPL、炎性脂质介质和SMase活性与眼表炎症和眼表炎症的临床特征
MGD和DE亚型。所产生的知识将通过确定相对的
不同脂质对DE不同表现的贡献,并为开发新的
治疗的分子靶点。
英文摘要
Dry eye (DE) affects 1 in 5 veterans and impacts quality of life. It is a complex disease that manifests with
multiple symptoms (e.g. pain, visual disturbance) and signs (e.g. decreased tear production, increased
evaporation). Key pathophysiological components of DE are ocular surface inflammation and meibomian gland
dysfunction (MGD). Despite its frequency and morbidity, current therapies do not relieve symptoms in all
patients. In order to appropriately manage DE, it is necessary to understand mechanisms and specific
contributors to disease sub-types. The overall goal of this proposal is to improve such knowledge by studying
the role of bioactive sphingolipids (SPL) in MGD and other aspects of DE. Our preliminary and published
work suggest SPL composition changes (higher sphingomyelin (SM)/ ceramide (Cer) ratio) in poor quality
meibomian gland secretion (meibum); a higher ratio of pro-inflammatory (ω-6) /pro-resolving (ω-3) lipids, and
higher levels of prostaglandin E2 in tears from DE patients. Bioactive Cer generated from SM by
sphingomyelinases (SMase) and its derivatives, ceramide 1-phosphate and sphingosine 1-phosphate are
inflammatory lipids and can induce formation of other inflammatory lipids such as prostaglandins. We detected
SMase activity in human tears. In this proposal, we will test the hypothesis that changes in SPL composition in
meibum contribute to various signs of DE including ocular surface inflammation, tear film disturbances, and
MGD. In Aim 1, we will profile meibum and tear SPL and pro- and anti-inflammatory PUFAs and eicosanoids
by LC-MS/MS from 120 cases (poor meibum quality) and 120 controls (normal meibum quality), chosen from
our prospectively collected samples from a large veteran population after a comprehensive eye evaluation
(mean age 62±10; 467 males, 46 females; 230 white, 272 black). Correlation and regression analysis will be
performed with clinical data as dependent variables and lipid mediators as independent variables. In Aim 2, we
will determine acitivity of SMAse (acidic and neutral) from 240 Schirmer's strips corresponding to the samples
in Aim 1. We will then build models looking at relationships between SMase activity, SPL, and ocular surface
inflammation. In Aim 3, we will identify molecular connections between SPL and inflammation in an in vitro
model by using human immortalized meibomian gland epithelial cell line (HMGEC) to test the effects of
bioactive SPL on mediating inflammation, cell viability, cell death etc. in normal and hyperosmolar conditions.
Impact: Our results will identify SPL differences by MGD status, elucidate relationships between bioactive
SPL, inflammatory lipid mediators, and SMase activity with ocular surface inflammation and clinical features of
MGD and DE sub-types. The knowledge generated will advance the field by determining the relative
contributions of different lipids on different manifestations of DE and provide the foundation for developing new
molecular targets for therapy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Defining bacterial members of the ocular surface microbiome and assessing stability over time
-
批准号:10668753
-
项目类别:
-
资助金额:$111.72万
-
财政年份:2023
-
负责人:Anat Galor
-
依托单位:
Lipid mediators and their signaling in ocular surface inflammation and meibomian gland dysfunction
-
批准号:10013711
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2020
-
负责人:Anat Galor
-
依托单位:
Neural mechanisms underlying photophobia and dry eye
-
批准号:10704725
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2020
-
负责人:Anat Galor
-
依托单位:
Neural mechanisms underlying photophobia and dry eye
-
批准号:10425233
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2020
-
负责人:Anat Galor
-
依托单位:
Lipid mediators and their signaling in ocular surface inflammation and meibomian gland dysfunction
-
批准号:10293544
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2020
-
负责人:Anat Galor
-
依托单位:
Neural mechanisms underlying photophobia and dry eye
-
批准号:9885368
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2020
-
负责人:Anat Galor
-
依托单位:
Dry Eye and Microenvironment
-
批准号:9176495
-
项目类别:
-
资助金额:$38.03万
-
财政年份:2016
-
负责人:Anat Galor
-
依托单位:
Dry Eye and Microenvironment
-
批准号:9325036
-
项目类别:
-
资助金额:$37.53万
-
财政年份:2016
-
负责人:Anat Galor
-
依托单位:
Dry Eye and Microenvironment
-
批准号:10011823
-
项目类别:
-
资助金额:$37.71万
-
财政年份:2016
-
负责人:Anat Galor
-
依托单位:
Dry Eye and Microenvironment
-
批准号:9767193
-
项目类别:
-
资助金额:$36.89万
-
财政年份:2016
-
负责人:Anat Galor
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: